Regeneus Ltd. (AU:CMB) has released an update.
Cyntec Co., Ltd. has emerged as a substantial holder in Cambium Bio Limited, securing an 8.2% stake with 62,966,489 fully paid ordinary shares. The acquisition, which positions Cyntec with significant voting power, involved a cash consideration of AUD 377,799. Orient EuroPharma Co., Ltd., as the parent company, holds an indirect interest through complete ownership of Cyntec.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.
